Boehringer Ingelheim Competitors and Similar CompaniesClear all
Daiichi Sankyo's competitors and similar companies include Pfizer and Lilly.
 Daiichi Sankyo Daiichi Sankyo (第一三共株式会社) is a company specializing in the research, development, and manufacture of innovative pharmaceutical products. |  Pfizer Pfizer is a research-based biopharmaceutical company engaged in the discovery, development, manufacture, and distribution of healthcare products. |  Lilly Eli Lilly is a company that discovers, develops, manufactures, and markets pharmaceutical products. | |
Founding Date | Founding Date 2005 | Founding Date 1849 | Founding Date 1876 |
Type | Type Public | Type Public | Type Public |
Tags | |||
Locations | Locations Tokyo, JP HQ Macquarie Park, AU Wien, AT Braine L'alleud, BE Sao Paulo, BR Toronto, CA Shanghai, CN see more | Locations New York, US HQ Buenos Aires, AR Villa Adelina, AR Footscray, AU Mulgrave, AU Sydney, AU Wien, AT see more | Locations Indianapolis, US HQ Buenos Aires, AR Sydney, AU Wien, AT Brussel, BE São Paulo, BR Toronto, CA see more |
Employees | Employees 18,726 | Employees 81,0008% decrease | Employees 47,0009% increase |
Valuation ($) | Valuation ($) 61.7 b | Valuation ($) 163.9 b | Valuation ($) 903.4 b |
Financial | |||
Revenue (est.) | Revenue (est.) ¥1.9t (FY, 2024) | Revenue (est.) $62.6b (FY, 2025) | Revenue (est.) $65.2b (FY, 2025) |
Cost of goods | Cost of goods ¥415.8b (FY, 2024) | Cost of goods $16.1b (FY, 2025) | Cost of goods $11.1b (FY, 2025) |
Gross profit | Gross profit ¥1.5t (FY, 2024) | Gross profit $46.5b (FY, 2025) | Gross profit $54.1b (FY, 2025) |
Net income | Net income ¥295.8b (FY, 2024) | Net income $7.8b (FY, 2025) | Net income $20.6b (FY, 2025) |
Operating ⚠ | |||
Countries | Countries N/A | Countries 200 (FY, 2024) | Countries 120 (FY, 2021) |
Phase I Trials Products | Phase I Trials Products 16 (FY, 2018) | Phase I Trials Products 51 (FY, 2024) | Phase I Trials Products 27 (FY, 2019) |
Phase II Trials Products | Phase II Trials Products 7 (FY, 2018) | Phase II Trials Products 27 (FY, 2024) | Phase II Trials Products 8 (FY, 2021) |
Phase III Trials Products | Phase III Trials Products 7 (FY, 2018) | Phase III Trials Products 32 (FY, 2024) | Phase III Trials Products 10 (FY, 2021) |
For sources of this data, please see the company profile
View Company Profiles
Pfizer
HQ
New York, US
Employees
81,000↓ 8% decrease
Pfizer is a research-based biopharmaceutical company engaged in the discovery, development, manufacture, and distribution of healthcare products.
View companyLilly
HQ
Indianapolis, US
Employees
47,000↑ 9% increase
Eli Lilly is a company that discovers, develops, manufactures, and markets pharmaceutical products.
View company